You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsing remitting Multiple sclerosis

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Los Angeles, California
    University of Southern California
Feb 3, 2022

Multiple Sclerosis (MS) Symptoms

Recruiting
  • Relapsing Remitting Multiple Sclerosis
    • Louisville, Kentucky
      University of Louisville (recruiting nationwide)
    Dec 13, 2021

    Multiple Sclerosis, Relapsing-Remitting Trial in Porto Alegre (Cladribine 10 mg oral tablet)

    Active, not recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • Cladribine 10 mg oral tablet
    • Porto Alegre, RS, Brazil
      Pontifical Catholic University of Rio Grande do Sul
    Jun 5, 2023

    Multiple Sclerosis, Relapsing-Remitting Trial in Switzerland (serum Neurofilament Filament Light chain (sNfL) monitoring)

    Not yet recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • serum Neurofilament Filament Light chain (sNfL) monitoring
    • Basel, Basel Stadt, Switzerland
    • +7 more
    Oct 17, 2023

    Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive Trial in Cleveland (Cionic

    Recruiting
    • Multiple Sclerosis
    • +2 more
    • Cionic Neural Sleeve NS-100
    • Actigraph accelerometer
    • Cleveland, Ohio
      Cleveland State University
    Jul 25, 2023

    A Post-Authorization, Long-term Study of Ozanimod Real-world

    Active, not recruiting
    • Multiple Sclerosis, Relapsing-Remitting
      • Bethesda, Maryland
        Evidera
      Oct 31, 2022

      Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Trial in Tokyo (OCH-NCNP1, Placebo)

      Active, not recruiting
      • Multiple Sclerosis, Relapsing-Remitting
      • Multiple Sclerosis, Secondary Progressive
      • Tokyo, Japan
        National Center of Neurology and Psychiatry
      Sep 28, 2022

      Multiple Sclerosis Trial in Amsterdam (MS Sherpa)

      Recruiting
      • Multiple Sclerosis
      • MS Sherpa
      • Amsterdam, Netherlands
        Amsterdam UMC, locatie VUmc
      Nov 4, 2023

      Cardiometabolic Health in Multiple Sclerosis

      Recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • Diepenbeek, Limburg, Belgium
          Hasselt University
        Mar 1, 2023

        Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)

        Active, not recruiting
        • Relapsing Remitting Multiple Sclerosis
        • Ublituximab
        • Pasadena, California
        • +7 more
        Aug 19, 2022

        Multiple Sclerosis, Relapsing-Remitting, Healthy Controls Trial in Garches (Neuropsychological tests and psychological

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Healthy Controls
        • Neuropsychological tests and psychological questionnaires
        • Garches, Hauts De Seine, France
          Hopital Raymond Poincaré Garches
        Dec 5, 2022

        Relapsing-remitting Multiple Sclerosis Trial (BCD-063, Copaxone-Teva, Placebo)

        Completed
        • Relapsing-remitting Multiple Sclerosis
        • (no location specified)
        Sep 8, 2021

        Multiple Sclerosis Trial in Baltimore (Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab)

        Recruiting
        • Multiple Sclerosis
        • Baltimore, Maryland
          Johns Hopkins University
        Oct 7, 2021

        Multiple Sclerosis (MS) Patients

        Not yet recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • +2 more
          • (no location specified)
          Dec 15, 2022

          Multiple Sclerosis Trial in Italy, Poland, United States (Ocrelizumab)

          Recruiting
          • Multiple Sclerosis
          • Loma Linda, California
          • +22 more
          Jan 13, 2023

          Relapsing Remitting Multiple Sclerosis Trial (Laquinimod, Avonex®)

          Withdrawn
          • Relapsing Remitting Multiple Sclerosis
          • (no location specified)
          Nov 5, 2021

          Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis

          Recruiting
          • Relapsing-Remitting Multiple Sclerosis
            • Coventry, United Kingdom
            • +7 more
            May 20, 2022

            Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,

            Terminated
            • Relapsing-Remitting Multiple Sclerosis
            • Autologous Hematopoietic Stem Cell Transplantation
            • +2 more
            • Hamburg, Germany
            • +1 more
            Mar 1, 2022

            Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Caen (Cognitive rehabilitation,

            Recruiting
            • Relapsing Remitting Multiple Sclerosis
            • Secondary Progressive Multiple Sclerosis
            • Cognitive rehabilitation
            • Standard Psychological care
            • Caen, Calvados, France
              University Hospital of Caen
            Mar 8, 2022

            Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS Trial in Amsterdam

            Recruiting
            • Multiple Sclerosis
            • +5 more
            • Amsterdam, Netherlands
              Amsterdam UMC, location VUmc
            Apr 17, 2023

            Multiple Sclerosis, Relapsing-Remitting Trial in Richardson (Transcranial Direct Current Stimulation, Sham transcranial direct

            Not yet recruiting
            • Multiple Sclerosis, Relapsing-Remitting
            • Transcranial Direct Current Stimulation
            • Sham transcranial direct current stimulation
            • Richardson, Texas
              The University of Texas at Dallas
            Jul 14, 2023

            Relapsing-remitting Multiple Sclerosis Trial in Berlin (epigallocatechin-gallate (Sunphenon), )

            Completed
            • Relapsing-remitting Multiple Sclerosis
            • epigallocatechin-gallate (Sunphenon)
            • placebo
            • Berlin, Germany
            • +1 more
            Jul 28, 2021

            Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

            Recruiting
            • Multiple Sclerosis, Relapsing-Remitting
            • West Orange, New Jersey
              Kessler Foundation
            Oct 12, 2022

            Relapsing-remitting Multiple Sclerosis (RRMS) Trial in New York (BeCare application)

            Recruiting
            • Relapsing-remitting Multiple Sclerosis (RRMS)
            • BeCare application
            • New York, New York
              Mount Sinai Hospital
            Dec 13, 2021

            Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Saint Louis (Cladribine)

            Recruiting
            • Multiple Sclerosis
            • Multiple Sclerosis, Relapsing-Remitting
            • Saint Louis, Missouri
            • +4 more
            Jan 4, 2023